Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / AGN:CC - Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

AGN:CC - Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals Inc.

--News Direct--

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of its escalating Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. The company is looking to investigate DMT for treatment of stroke and traumatic brain injury.

Moreau telling Proactive the committee tasked with reviewing the program has confirmed that there were no safety or tolerability issues with the highest dose, which was able to maintain plasma DMT concentrations at targeted levels and which was below the established psychedelic dose.

The company says the second part of the study will include dosing subjects for 6 hours with repeated administrations over a two-week period which can be used in its first Phase 2 study for stroke and TBI.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/algernon-pharmaceuticals-plans-phase-2-stroke-and-tbi-study-after-successful-dmt-single-dose-study-262596601

Stock Information
Company Name: Algernon Pharmaceuticals Inc.
Stock Symbol: AGN:CC
Market: CNQC
Menu
AGN:CC AGN:CC Quote AGN:CC Short AGN:CC News AGN:CC Articles AGN:CC Message Board
Get AGN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...